Technology ID
TAB-4591

Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer

E-Numbers
E-043-2016-0
Lead Inventor
Van Waes, Carter (NIDCD)
Co-Inventors
Saleh, Anthony (miRecule, Inc)
Cheng, Hui (NIDCD)
Chen, Zhong (NIDCD)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Oncology
Development Stages
Pre-clinical (in vivo)
Lead IC
NIDCD
ICs
NIDCD

This technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets. Utilizing the recently published data from 279 tumor specimens, this analysis strategy identified 9 potentially therapeutic microRNAs, four of which were members of the miR-30-5p family. To further validate its role in tumor suppression, several classical oncogenes centering on Receptor tyrosine kinase (RTK) signaling as novel targets of miR-30 and display regulation both in vitro and in vivo were identified. Finally, its validity as a therapeutic target is supported by showing strong tumor growth delay for a synthetic miR-30a-5p mimic in a xenograft tumor model of HNSCC.

Commercial Applications
Agents to be used in the treatment of cancer, either alone or in combination with chemotherapy/radiation, in addition to a companion diagnostic test.

Competitive Advantages
The greatest advantage of such a therapeutic would be the ability to target and repress multiple driving oncogenic pathways simultaneously, reducing the chances of resistance.
Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov